NASDAQ OMX

IPsoft Launches Amelia Healthcare Practice to Transform the Healthcare Workforce and Patient Experience with Cognitive AI

Dela

NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leading digital labor company, is to launch a vertically focused portfolio of solutions for the healthcare industry based on its AI platform, Amelia. A series of Amelia Health Agent offerings are under development in a program of co-collaboration with healthcare providers, health systems, health insurers and life sciences organizations. The first releases will target high volume processes and interactions that will deliver tangible improvements for providers, insurers, carers and patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/04fe91f2-5d18-475f-b43e-7d1183aaba1b

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4758c05a-915d-4278-8f55-6ed323f7649f

A video accompanying this announcement is available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/1be90122-0c3d-499e-9a10-80da9d5262b5

The new practice builds on the positive results of Amelia implementations across industries to target the healthcare AI market, which is expected to reach $6.6 billion by 20211. 

"We have seen the hype about AI's ability to find cures for major diseases overnight.  Now it is time to recover AI's reputation by applying advanced cognitive technology to the daily operations of the sector in order to provide demonstrable benefits to patients and the organizations who treat them," said Chetan Dube, IPsoft President and CEO.  

In order to develop and lead this new global practice, IPsoft has appointed David Champeaux as its global Cognitive Director, Healthcare Solutions. David has deep experience in designing and leading technology-enabled transformations within the healthcare sector both in his previous role as a Partner in McKinsey & Company's Healthcare practice and McKinsey Digital, where he served clients in Europe, Australia and the US, and as Managing Director leading Accenture's UK Healthcare Strategy practice.

"Routine cognitive processes can take up to 51% of a nurse's and 17% of a doctor's time - which is frustrating when Health Systems struggle with affordability and workforce shortages and patients complain about access. With Amelia's unique combination of human-like conversational intelligence, advanced analytics and dynamic processes execution, we finally have the opportunity to transform healthcare by freeing up its human capital - addressing challenges in access, quality, and efficiency," said David Champeaux.

In hospitals, Amelia can have significant and immediate impact relieving those who should be caring for patients from routine interactions, by helping manage operational and administrative processes such as booking rooms and beds or coordinating patient transfers.

For chronic conditions, which account for 86%2 of healthcare spend in the US, Amelia can help health institutions establish sustainable delivery at scale of proactive, coordinated patient care plans. For example, she can streamline most administrative and operational arrangements, such as providing information, booking regular appointments and scheduling tests.

For health insurers, Amelia can help improve the customer experience and efficiency of routine member services. Amelia can deliver affordable 24/7 availability to answer eligibility and coverage questions, or initiate and manage claims. In parallel, by employing Amelia, health insurance providers will be able to connect back-end underwriting systems and processes to every customer conversation, delivering instant scale to their operations.

Amelia is the most human and comprehensive AI platform on the market. Uniquely, Amelia connects conversations to data and processes in order to provide a personalized service to every customer, at scale. Across the US, Europe and Asia, global organizations are employing Amelia to improve customer experience and drive enhanced productivity.

To learn more about how Amelia can transform business operations and customer interactions, visit ipsoft.com/amelia

About IPsoft
IPsoft automates IT and business processes for enterprises across a wide range of industries through the use of digital labor. Through its portfolio of world leading autonomic and cognitive solutions it provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has offices in 18 countries across the world and serves more than 500 of the world's leading companies directly as well as more than half of the world's largest IT services providers. To learn more about IPsoft's solutions please visit www.ipsoft.com.

Contacts

IPsoft
Daniela Zuin, 212-708-5521
Mobile: 917-822-0484
daniela.zuin@ipsoft.com
or
Finn Partners for IPsoft
Erica McDonald, 646-202-9784
Mobile: 732-713-2354
Erica.mcdonald@finnpartners.com

Frost & Sullivan, Artificial Intelligence & Cognitive Computing Systems in Healthcare

2 Centers for Disease Control and Prevention (CDC) Website Data




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit15.12.2017 22:04Pressmeddelande

Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt Stock Exchange:QIA) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million.  The settlement includes general

Algeco Scotsman Announces Acquisition of Iron Horse Ranch15.12.2017 21:32Pressmeddelande

BALTIMORE, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced the successful closing of the acquisition by the Algeco Group's subsidiary, Target Logistics Management, LLC ("Target Logistics"), of Iron Horse Ranch from funds managed by TDR Capital LLP ("TDR"). The acquisition solidifies Target Logistics' position as the single largest provider of turnkey workforce housing in the U.S., including a network of eight lodges and 2,119 beds in the Permian Basin. With the acquisition, Target Logistics' Permian Basin lodge network now includes Texas lodges in Pecos, Mentone, San Angelo and two in Odessa, along with two lodges in Carlsbad and Lovington, New Mexico. Additionally, Target Logistics adds Eagle Ford lodges in Cameron and Yorktown, Texas. Diarmuid Cummins, CEO Algeco Scotsman: "Today we announce the completion of the second of two strategic acquisitions which we flagged earlier

Repurchase of own shares in Momentum Group AB (publ)15.12.2017 15:25Pressmeddelande

In accordance with the authorisation issued by the Extraordinary General Meeting of Shareholders held on 28 November 2017, Momentum Group AB (publ) has repurchased 28,800 Class B shares at an average price of SEK 103.34 per share. After the repurchase, Momentum Group AB's current holding of treasury shares amounts to 28,800 Class B shares, corresponding to 0.1 percent of the total number of shares and 0.1 percent of the total number of votes. The total number of shares in Momentum Group AB, including those held by the Company, amounts to 28,265,416, of which 1,062,436 are Class A shares and 27,202,980 are Class B shares. The total number of votes in Momentum Group AB is 37,827,340. Stockholm, 15 December 2017 Momentum Group AB (publ) For further information, please contact: Mats Karlqvist, Head of Investor Relations - Tel: +46 70 660 31 32 This information was submitted for publication on 15 December 201

Återköp av egna aktier i Momentum Group AB (publ)15.12.2017 15:25Pressmeddelande

I enlighet med bemyndigandet från den extra bolagsstämman den 28 november 2017 har Momentum Group AB (publ) återköpt 28 800 aktier av serie B till en genomsnittskurs av 103,34 SEK per aktie. Momentum Group ABs aktuella innehav av egna aktier efter återköpet uppgår till 28 800 aktier av serie B, vilket motsvarar 0,1 procent av totalt antal aktier och 0,1 procent av totalt antal röster. Det totala antalet aktier i Momentum Group AB, inklusive de av bolaget ägda aktierna, uppgår till 28 265 416 st, av vilka 1 062 436 är aktier av serie A och 27 202 980 är aktier av serie B. Det totala antalet röster i Momentum Group AB är 37 827 340. Stockholm den 15 december 2017 Momentum Group AB (publ) För ytterligare information vänligen kontakta: Mats Karlqvist, Head of Investor Relations - telefon 070-660 31 32 Informationen lämnades för offentliggörande den 15 december 2017 kl. 15:15 CET.  

Elemica Named to Food Logistics Top 100 List15.12.2017 13:55Pressmeddelande

11th Consecutive Win for Delivering Value Across Clients' Supply Chains WAYNE, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading  Business Network for the process industries, announces the company has been named to Food Logistics magazine's FL100+ Award for the 11th year. The FL100+ list recognizes leading software and technology providers in the food and beverage industry.  Elemica was chosen for helping agricultural and food ingredient businesses conduct more efficient and error free commerce across their community of suppliers, customers and logistics providers - delivering value through lower operating expenses and working capital costs. "We are honored to be included for the past eleven years on the Food Logistics FL100+ list for helping companies improve efficiencies and generate value from their supply chains," said John Blyzinskyj, CEO of Elemica. "Automating business processes, enabling end-to-end visibility, and providing a platform for

LeoVegas expands into new, state-of-the-art and larger premises in Stockholm15.12.2017 12:20Pressmeddelande

LeoVegas more than triples the size of its Swedish headquarters and invests heavily in expanding its technology and product organization in Stockholm. The move enables continued and rapid growth and strengthens LeoVegas position as Sweden's leading GameTech company. Gustaf Hagman, LeoVegas' Group CEO, comments: "As an early Christmas gift to all amazing employees, we today move into a 'top of the line office' full of energy. LeoVegas is today an attractive employer who continuously attracts top talent. Our strong corporate culture and growth journey continues!" says Gustaf Hagman, Group CEO. LeoVegas now has close to 4000 square meters in Sweden, which enables continued recruitment of the technology sector's most innovative developers within mobile gaming. The new area in Stockholm has been completely renovated to meet LeoVegas' high standard requirements. The move enables LeoVegas to have 300-350 developers in Sweden compared to today's approximately 120.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum